Evidence map›Paper›PMID 37519310›Full record

ArticlePublic health challenges2022

Road to achieving COVID-19 herd immunity in Niger Republic: Challenges and recommendations.

Sil-Ana Salissou Abdou, Oladunni Abimbola Amos, Ogechi Vida Onwuemene, Goodness Ogeyi Odey, Caleb James Nsikak Abasi

Open access · diamondAbstract read
In one paragraph

Article in Public health challenges, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Sil-Ana Salissou AbdouFaculty of Health Sciences, department of Nursing and midwifery Aboubacar Ibrahim International University Maradi Maradi Niger Republic.
Oladunni Abimbola AmosDepartment of Pharmacology and Therapeutics College of Medicine University of Ibadan, Ibadan, Oyo state Nigeria.ORCID https://orcid.org/0000-0002-6023-3725
Ogechi Vida OnwuemeneDepartment of Public Health University of Calabar Calabar Nigeria.
Goodness Ogeyi OdeyDepartment of Public Health University of Calabar Calabar Nigeria.ORCID https://orcid.org/0000-0002-2374-9909
Caleb James Nsikak AbasiFaculty of Pharmacy University of Uyo, Uyo, Akwa Ibom Nigeria.
University of Calabar · NGUniversité de Maradi · NEUniversity of Ibadan · NGUniversity of Uyo · NG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 pandemic has had tremendous impact on countries across the world and Niger Republic is not left out of the ravaging impact of the virus. The rapid dissemination of the virus across the globe has led to the development of safe and efficacious vaccines at an unprecedented level. While Niger Republic has prioritized COVID-19 vaccination in line with the global plan to attain herd immunity by vaccinating 70% of world's population, the country has continued to struggle to expand coverage of its population. Niger Republic is faced with challenges such as conflict, COVID-19 vaccine hesitancy, poor COVID-19 vaccine demand and inefficient information system, consequently leading to low COVID-19 vaccine demand and uptake. These challenges coupled with the different wave of the pandemic, the latest largely driven by the Omicron variant has slowed down progress towards achieving herd immunity in Niger Republic. There is need for the Nigerien government to scale up vaccination drive as well as implement refined approaches towards achieving the country's herd immunity target. This paper aimed to discuss the current state of COVID-19 vaccination including efforts and challenges towards achieving herd immunity in Niger Republic, thus informing strategies to ramp up COVID-19 vaccination in the country.

Indexed as

COVID‐19herd immunityNiger Republicvaccine

Identifiers

PMID37519310
PMCPMC9877972
OpenAlexW4311175543

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.